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                                                INTRODUCTION 
 
Atrial fibrillation constitutes the commonest cardiac rhythm disorder and is the major 
determinant of Outcome in valvular, myocardial, and ischemic heart disorders. There is 
no simple tool available to predict the onset this arrhythmia.  
 
Electrophysiological parameters are too complex and can not be obtained in bedside.  
 
Tissue Doppler analysis of atrial muscle gives us an opportunity to measure the critical 
total atrial conduction time non invasively. 
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                                   AIM 
 
To predict new-onset Atrial Fibrillation (AF) by measuring the total atrial conduction 
time by atrial tissue Doppler imaging. 
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                                   REVIEW OF LITERATURE 
 
HISTORY OF ECHOCARDIOGRAPHY 
                            Many histories of diagnostic ultrasound9 and cardiac ultrasound in 
particular, have been written. They all seem to address this field from a different 
perspective. One can begin the history in the twentieth century, Roman times, or any of 
the centuries in between. It is stated that a Roman architect, Vitruvius, first coined the 
word echo. A Franciscan friar, Marin Mersenne (1588-“1648), is frequently called the 
father of acoustics because he first measured the velocity of sound. Another early 
physicist, Robert Boyle (1627-1691), recognized that a medium was necessary for the 
propagation of sound. Abbe Lazzaro Spallanzani (1727-1799) is frequently referred to as 
the father of ultrasound. He demonstrated that bats were blind and in fact navigated by 
means of echo reflection using inaudible sound. In 1842, Christian Johann Doppler 
(1803-1853) noted that the pitch of a sound wave varied if the source of the sound was 
moving. He worked out the mathematical relationship between the pitch and the relative 
motion of the source and the observer. The ability to create ultrasonic waves came in 
1880 with the discovery of piezoelectricity by Curie and Curie. They noted that if certain 
crystalline materials are compressed, an electric charge is produced between the opposite 
surfaces. They then noted that the reverse was also true. If an electrical potential is 
applied to a crystal, it is compressed and decompressed depending on the polarity of the 
electric charge, and thus very high frequency sound can be produced. In 1912, a British 
engineer, L. F. Richardson, suggested that an echo technique could be used to de- tect 
underwater objects. Later during World War I, Paul Langevin was given the duty of 
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detecting enemy submarines using sound, which culminated in the development of sonar. 
Sokolov described a method for using reflected sound to detect metal flaws in 1929. In 
1942, Floyd Firestone, an American engineer, began to apply this technique and received 
a patent. It is this flaw detection technique that ultimately was used in medicine. 
An Austrian, Karl Dussik, was probably the first to apply ultrasound for medical 
diagnosis in 1941. He initially attempted to outline the ventricles of the brain. His 
approach used transmission ultrasound rather than reflected ultrasound. After World War 
II, many of the technologies developed during that war, including sonar, were applied for 
peaceful and medical uses. In 1950, W. D. Keidel, a German investigator, used 
ultrasound to examine the heart. His technique was to transmit ultrasonic waves through 
the heart and record the effect of ultrasound on the other side of the chest. The purpose of 
his work was to try to determine cardiac volumes. The first effort to use pulse-reflected 
ultrasound, as described by Firestone, to examine the heart was initiated by Dr. Helmut 
Hertz of Sweden. He was familiar with Firestone's observations and in 1953 obtained a 
commercial ultrasonoscope, which was being used for nondestructive testing. He then 
collaborated with Dr. Inge Edler who was a practicing cardiologist in Lund, Sweden. The 
two of them began to use this commercial ultrasonoscope to examine the heart. This 
collaboration is commonly accepted as the beginning of clinical echocardiography as we 
know it today. 
                 The original instrument9 was quite insensitive. The only cardiac structures that 
they could record initially were from the back wall of the heart. In retrospect, these 
echoes probably came from the posterior left ventricular wall. With some modification of 
their instrument, they were able to record an echo from the anterior leaflet of the mitral 
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valve. However, they did not recognize the source of this echo for several years and 
originally attributed the signal to the anterior left atrial wall. Only after some autopsy 
investigations did they recognize the echo's true origin. Edler went on to perform a 
number of ultrasonic studies of the heart. Many of the cardiac echoes currently used were 
first described by him. However, the principal clinical application of echocardiography 
developed by Edler was the detection of mitral stenosis. He noted that there was a 
difference between the pattern of motion of the anterior mitral leaflet in patients who did 
or did not have mitral stenosis. Thus, the early studies published in the mid-1950s and 
early 1960s primarily dealt with the detection of this disorder. 
                   The work being done in Sweden was duplicated by a group in Germany 
headed by Dr. Sven Effert. Their publications began to appear in the late 1950s and were 
primarily duplications of Edler's work describing mitral stenosis. One notable observation 
made by Effert and his group was the detection of left atrial masses. Schmitt and Braun in 
Germany also began working with ultrasound cardiography and published their work in 
1958, again repeating what Edler and Effert had been doing. Edler and his co-workers 
developed a scientific film that was shown at the Third European Congress of Cardiology 
in Rome in 1960. Edler et al. also wrote a large review of cardiac ultrasound as a 
supplement to Acta Medica Scandinavica, which was published in 1961, and remained 
the most comprehensive review of this field for more than 10 years. In the movie and the 
review, Edler and his co-investigators described the ultrasonic techniques for the 
detection of mitral stenosis, left atrial tumors, aortic stenosis, and anterior pericardial 
effusion. 
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Despite their initial efforts at using ultrasound to examine the heart, neither Edler nor 
Hertz really anticipated that this technique would flourish. Helmut Hertz was primarily 
interested in being able to record the ultrasonic signals. In the process, he developed ink 
jet technology and only spent a few years in the field of cardiac ultrasound. He devoted 
most of the rest of his career to ink jet technology, for which he held many important 
patents. He also advised Siemens Corporation, who provided their first ultrasonic 
instrument, that they should not enter the field of cardiac ultrasound because he 
personally did not feel that there was a great future in this area (Effert, personal 
communication, 1996). Edler too did not develop any further techniques in cardiac 
ultrasound. He retired in 1976 and until then was primarily concerned with the 
application of echocardiography for mitral stenosis and, to a lesser extent, mitral 
regurgitation. He never became involved with any of the newer techniques for pericardial 
effusion or ventricular function. 
 
DOPPLER TISSUE IMAGING9 
                     Routine Doppler imaging typically targets blood flow and hence the receiver 
characteristics, including the frequency filters that determine the range of velocities to be 
interrogated, are set to maximize the shifts anticipated with moving blood and to exclude 
the velocity shifts that would be seen with slower moving structures. Because red blood 
cells are relatively weak reflectors and tissue is a fairly intense reflector, filters are also 
adjusted to exclude highly reflective objects and to maximize less reflective objects when 
using conventional Doppler. Doppler tissue imaging uses the same principles; however, 
the target is tissue rather than red blood cells. For this purpose, filters are set to 
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parameters opposite those needed to accurately detect red blood cell motion. Because 
tissue has a greater reflectivity and slower motion, instrumentation filters are set to 
exclude high velocities and low-intensity reflectors. With this technique, either the 
myocardium or fibrous skeleton of the heart can be targeted and weaker reflections from 
the higher velocity blood cells relatively excluded. 
                          One of the initial applications of this technique was to use color flow 
imaging display methodology and to saturate an area of interest with Doppler 
interrogation. The color Doppler signal from the moving tissue was then superimposed 
on the two-dimensional gray-scale image. Using traditional blue-red encoding for 
direction of motion, this results in dissimilar color encoding even when walls are moving 
at a similar velocity. The normally moving ventricular septum will be encoded in blue 
(motion away from the transducer), and the normal anterior motion of the posterior wall 
will be encoded in red. This results in opposite color encoding of opposing walls, which 
each have normal directional motion. The color encoding scheme can be changed to be 
unidirectional, recording only velocity irrespective of direction, in the same color. This 
has the disadvantage of encoding a dyskinetic wall with the same color as a normally 
contracting wall. This technique has substantial potential in that it would allow 
superimposing information regarding velocity and direction of motion on the anatomic 
image. It is limited in its applicability by relatively low frame rates and the inability to 
fully saturate the signal. Other limitations include potential aliasing of the color signal 
with higher velocity motion and limited registration of velocity information at an angle of 
incidence (Î¸) exceeding 30 degrees. Signal-to-noise ratios are typically relatively low, 
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and in poor-quality images, there may be substantial bleeding of the color signal from the 
tissue into the blood pool. 
                       The initial attempts at color encoding and Doppler tissue imaging used 
standard Doppler shifts of velocity. The Doppler signal in the power or energy domain 
can also be encoded. The power domain refers to the registration of the intensity or 
amplitude of the reflected Doppler shifts rather than just their velocity. In theory, this 
format may be of benefit because of its higher signal-to-noise ratio and has been used 
fairly extensively in contrast echocardiography. 
                      Complete saturation of the image with color signal has seen little clinical 
acceptance because of the limitations of frame rate and saturation with an adequate 
signal-to-noise ratio. It should be recognized that the original source signal is actually 
pulsed Doppler information, acquired from a wide area of interest and targeted to tissue 
motion. A greater degree of acceptance has been seen by displaying the spectral signal of 
velocity and extracting quantitative information from localized areas using this technique. 
Analogous to the use of a sample volume in blood flow imaging, a sample volume can be 
placed within the myocardium or mitral or tricuspid anulus and the direction and velocity 
of the myocardium at that point in space accurately determined. 
                     A variation on Doppler tissue imaging is to acquire color-encoded images of 
tissue motion along an M-mode interrogation line. This represents a combination of M-
mode echocardiography, color Doppler imaging, and quantitative Doppler tissue imaging. 
Color tissue Doppler M-mode imaging is a high temporal and spatial resolution  
technique for investigating myocardial mechanics, and the information thus extracted can 
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secondarily be employed for determining velocity gradients between adjacent points or 
more recently for strain rate imaging. 
                       As Doppler imaging inherently detects motion and determines velocity, 
this is the fundamental parameter available. From this displacement of the tissue, the 
distance traveled can be determined as the product of velocity and time. More complex 
derivatives of the velocity determination include the calculation of the velocity gradient 
between two points and strain or strain rate imaging, which are measures of tissue 
deformation. The simplest calculation that can be derived from two-point analysis is the 
absolute difference in velocities. This has had clinical applicability in determining the 
gradient between endocardial and epicardial velocities, which may be a more sensitive 
indicator of myocardial ischemia than an absolute decrease in velocity across the entire 
myocardial wall. 
                       More complex derivatives of these measurements include strain and strain 
rate, both of which are more load independent than parameters such as ejection fraction 
and wall motion and provide a more direct assessment of myocardial contractility. 
Because strain rate refers to the first derivative of motion (i.e., velocity change), it is 
more directly derived from Doppler tissue imaging, which inherently is a velocity 
calculation. strain is defined as the change in distance between two points divided by the 
initial length (L0). Mathematically, it is a unitless number. Strain rate is the first 
derivative of strain and is calculated as the change in velocity between two points divided 
by the distance (L) between the two points. Mathematically, the units of strain rate are1/s. 
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                       Displacement, strain, and strain rate can be displayed in several formats. 
The easiest to understand is a graphic output of either of these parameters over time. One 
or more discrete regions of interest can be identified and simultaneously graphed for 
comparison of displacement, strain, or strain rate at any given time point. Because these 
parameters are derived from tissue Doppler imaging, which has high spatial resolution, it 
is often beneficial to simultaneously display these values for multiple points throughout 
the ventricular myocardium or for all points along a continuous line drawn through the 
myocardium. Display of this type of information requires a different format than a simple 
x/y graph as is appropriate for a single point. M-mode display in which time is 
conventionally displayed on the x axis, distance around the ventricle on the y axis, and 
the value of displacement, strain, or strain rate in color. This is analogous to the display 
of Doppler velocity data in a color M-mode but obviously incorporates the third 
dimension of location within the heart. Numerous studies have demonstrated that Doppler 
imaging  derived myocardial gradients as well as strain and strain rate provide a higher 
resolution evaluation of myocardial mechanics than evaluation of wall motion, 
myocardial thickening, or tissue velocities alone. 
 
                       Tissue Doppler imaging (TDI) 8 is a novel use of ultrasound to image the 
motion of tissue with Doppler echocardiography. Doppler echocardiography records and 
displays the velocities of the moving targets. When Doppler echocardiography is used to 
measure blood flow velocity, erythrocytes are the targets. Their normal velocity ranges 
from 10 cm/s in the venous circulation to 150 cm/s in the arterial circulation. However, 
the velocities of myocardial tissue are much lower (1-20 cm/s), but their amplitudes are 
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greater than those produced by blood. Therefore, Doppler ultrasound instruments high 
frame rate. A special function key needs to be selected to activate TDI. After TDI has 
been selected, the subsequent operation is identical to that used to perform regular pulsed 
wave Doppler echocardiography, except that the TDI gain needs to be lowered from the 
regular gain setting used for blood flow Doppler recordings and the velocity scale needs 
to be adjusted to a lower aliasing velocity (about 20-30 cm/s or even lower) to optimize 
TDI signals. Some ultrasound units adjust these variables automatically when the TDI 
function is selected. Also, TDI can be displayed in the color mode, just as in color 
imaging of blood flow. Tissue velocities are color-coded by autocorrelation: red for tissue 
moving toward the transducer and blue for tissue moving away from the transducer. 
Movement and velocities of cardiac structures are regulated by the underlying systolic 
function and diastolic function of the heart. Isaaz and colleagues were able to obtain a 
pulsed Doppler profile of the left ventricular (LV) posterior wall. This was expanded by 
McDicken and colleagues (who developed a prototype of color Doppler velocity display 
of myocardial wall dynamics). Currently, TDI is an integral part of an echocardiography 
examination in the areas discussed in the following sections. 
 
ASSESSMENT OF MYOCARDIAL RELAXATION8 
                       Early diastolic velocity (Ea) of the mitral anulus measured with TDI is a 
good indicator of LV myocardial relaxation. This is one of the most important 
components of myocardial diastolic function the mitral anulus can be appreciated visually 
from the parasternal long-axis and apical four-chamber views, but TDI records and 
demonstrates the velocity of the longitudinal motion in numerical value. In the normal 
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heart with normal myocardial relaxation, Ea  increases with an increasing transmitral 
gradient, increasing preload, exercise, and dobutamine infusion . However, when 
myocardial relaxation is impaired because of aging or a disease process, Ea is affected 
less or even unchanged by preload or transmitral gradient. Velocities of longitudinal 
mitral anulus motion are best obtained from apical views. Although various locations of 
the mitral anulus can be interrogated with TDI, the two most frequently used locations 
are the septal (or medial) and lateral mitral anulus. Usually, Ea from the lateral anulus is 
higher (normally >15 cm/s) than that from the medial anulus (normally >10 cm/s). In our 
laboratory, mitral anulus velocities are usually, but not always, obtained from the septal 
anulus. Regional myocardial dysfunction or valvular surgery involving the mitral anulus 
may affect mitral anulus velocities. A localized disease process, such as lateral 
myocardial infarction, can result in mitral anulus velocities being lower at the lateral 
anulus than at the septal anulus. 
Table 1 
Comparison of two-dimensional (2D) gray scale and tissue doppler imaging (TDI) 
    TDI 
Variable 2D Gray Scale Color Doppler 
Pulsed 
Doppler 
Temporal resolution 30-50 frames/s (but 400 
frames/s possible) 
20-90 frames/s >150 
frames/s possible) 
>250 
frames/s 
Spatial resolution 1 ×1 mm (may be less) Typically 2 × 2 mm 1 ×1 mm 
Angle dependency No Yes Yes 
Applicability to all 
myocardium 
++ +++ +++ 
Intramural function No Yes No 
Attenuation 
dependency 
++++ ++ + 
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Late diastolic velocity (Aa ) of the mitral anulus8 at the time of atrial contraction 
increases during early diastolic dysfunction, as is the case for the mitral inflow A wave, 
but decreases as atrial function deteriorates. Aa has been correlated with left atrial (LA) 
function. 
 
ESTIMATION OF LEFT VENTRICULAR FILLING PRESSURE8 
 
                      LV diastolic filling pressures can be estimated reliably with 2D and 
Doppler echocardiography. The deceleration time (DT) of mitral inflow early diastolic 
velocity (E) has a good inverse correlation with the pulmonary capillary wedge pressure 
(PCWP) of less than 130 milliseconds usually indicate a PCWP greater than 20 mm Hg. 
However, mitral inflow DT alone is not highly accurate in patients who have a relatively 
normal LVEF or atrial fibrillation. Because Ea is reduced in patients with impaired 
relaxation and is affected less by preload than mitral inflow E, the ratio (E/Ea) between 
mitral inflow early diastolic velocity and mitral anulus early diastolic velocity increases 
as PCWP increases. Investigations at Baylor College and in our laboratory have 
demonstrated that PCWP is higher than 20 mm Hg when E/Ea is more than 10 (using the 
lateral anulus Ea) or 15 (using the medial anulus Ea). This ratio works well even in 
patients who have fused mitral inflow signals, preserved LVEF, and atrial fibrillation. 
The only exception is patients with constrictive pericarditis, in whom Ea, especially from 
the medial anulus, is increased (>8 cm/s) and E/Ea is reduced with high filling pressures. 
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Because PCWP can be estimated reliably with E/Ea, estimation of PCWP with exercise is 
feasible (which is helpful is assessing patients who have exertional dyspnea). 
 
EVALUATION OF REGIONAL AND GLOBAL SYSTOLIC FUNCTION 
 
                      The extent of systolic movement of the mitral anulus correlates with LV 
systolic function and stroke volume. Normally, the systolic velocity (Sa) of the mitral 
anulus is more than 6 cm/s. Although TDI of the mitral anulus reflects the global systolic 
and diastolic function of the LV, segmental or regional function can be assessed by 
performing TDI of various LV segments by placing the sample volume (2-5 mm) in the 
region of interest. The size of the sample volume depends on the location and intensity of 
the signal and is usually between 2 and 5 mm. Further clinical experience with this 
variable will determine if Sa can replace other more commonly used systolic variables. 
 
TISSUE VELOCITY GRADIENT 
 
                      TDI can measure the difference in velocities of adjacent myocardial tissues 
(velocity gradient), and this can be used to assess the viability and deformation (strain) of 
the myocardium. The velocity of the endocardium is normally higher than that of the 
epicardium, thus producing a tissue velocity gradient. In akinetic but viable or 
nontransmurally infarcted myocardium, the myocardial velocity gradient persists, but 
there is no velocity gradient in scarred or transmurally infarcted myocardium. Because 
days to weeks are needed for myocardial contractility to recover after successful 
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reperfusion of an occluded coronary artery, measurement of the tissue velocity gradient 
can be useful in patients with an acute myocardial infarction. To record or display the 
myocardial velocity gradient, the direction of myocardial contractility needs to be aligned 
in parallel with the direction of the ultrasound beam. Therefore, imaging views are 
limited to the parasternal windows to image anterior or posterior walls. 
 
CARDIAC TIME INTERVALS 
 
                       Cardiac time intervals are regulated precisely by the mechanics and 
functions of the myocytes; hence, these intervals are a good measure of cardiac function. 
TDI is well suited for determining the timing of myocardial events. The precise timing of 
these events is helpful in understanding the mechanism of myocardial relaxation and 
myocardial suction during early diastolic filling. In healthy hearts, in which efficient 
myocardial relaxation is used effectively to suck blood from the LA into the LV during 
early diastole, the time of onset of mitral inflow (E) coincides with that of myocardial 
early diastolic motion (relaxation) of the mitral anulus (Ea). However, in hearts with 
delayed myocardial relaxation and increased filling pressure, diastolic filling (onset of the 
E wave) depends more on the increased LA pressure and occurs earlier than the onset of 
the early diastolic motion of the mitral anulus (Ea). Therefore, the time interval between 
the onset of mitral E velocity and that of the mitral anulus diastolic motion (Ea) increases, 
and this increased interval has been proposed as a new variable to assess LV filling 
pressures. 
 21
A limitation of measuring cardiac time intervals by pulsed wave Doppler 
echocardiography is nonsimultaneity because different cardiac cycles are usually needed 
to measure various intervals which in turn are used together. One solution is to have the 
capability of obtaining multiple pulsed wave Doppler recordings simultaneously. Another 
creative means to measure cardiac intervals from a single cardiac cycle is to use tissue 
Doppler anatomic color M-mode from the anterior mitral leaflet. From this technique, 
isovolumic contraction time, isovolumic relaxation time, and LV ejection time can be 
measured reliably from a single cardiac cycle 
                       Mechanical dyssynchrony is measured by time intervals between peak 
ejection systolic velocities or peak strain of multiple myocardial segments, as discussed 
below. 
 
EVALUATION OF THICK WALLS 
 
                       The ventricular walls become thick for several reasons including LV 
hypertrophy, hypertrophic cardiomyopathy, infiltrative cardiomyopathy, restrictive 
cardiomyopathy, and the athletic heart. These entities can usually be differentiated on the 
basis of clinical and laboratory findings, but differentiating them can occasionally be 
difficult. The evaluation of myocardial relaxation with TDI is able to distinguish between 
a thick athletic normal heart and other disease conditions (16). Mitral anulus motion is 
well preserved in the athletic heart because myocardial relaxation is preserved, but it is 
reduced in all other conditions that have impaired myocardial relaxation. 
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PROGNOSTICATION 
                        Because E/Ea can estimate LV filling pressures and patients with 
increased filling pressures have higher rates of morbidity and mortality, it is expected that 
a high E/Ea predicts a poor outcome. E/Ea more than 15 was found to be associated with 
increased mortality of patients with acute myocardial infarction . By itself, Ea is also a 
good predictor for clinical outcome. In various clinical conditions, patients who have an 
Ea less than 5 cm/s are more likely to have a much higher mortality than those with an Ea 
more than 5 cm/s. 
 
STRAIN AND STRAIN RATE IMAGING 
 
                      Myocardial velocities measured with TDI may be overestimated or 
underestimated by translational motion or tethering of the myocardium, respectively. This 
limitation can be overcome by measuring the actual extent of myocardial deformation 
(stretching or contraction) by strain (Îµ) and strain rate imaging (Fig. 5-3). Strain rate is 
the rate of change in length calculated as the difference between two velocities 
normalized to the distance between them; it is expressed as seconds-1. By convention, 
shortening is represented by negative values and lengthening by positive values for both 
strain and strain rate: 
Strain rate = (Va - Vb)/d 
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Where Va - Vb is the instantaneous velocity difference at points a and b, and d is the 
distance between the two points. 
Strain (ε) is the percentage change in length during myocardial contraction and relaxation 
and is expressed as a percentage: 
                                              ε = (L1- L0 ) / L0 
                                                                          = ∆L / L0 
 
where L0 is the original length, L1 is the final length, and ∆L is the change in length. 
Strain can be derived echocardiographically by the following: 
 
                                              ε = ∫tto SR.dt 
 
Where strain (ε) is the sum of the instantaneous strain rate (SR) values from starting time 
(t0) to ending time (t). 
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FIGURE 1A, Recording of tissue velocity. The sample volume was placed at the basal portion of the 
inferior septum. Peak systolic velocity (Sm) was slightly more than 6cm/sec, early diastolic velocity 
(Em) was 10cm/sec, and late diastolic velocity (Am) was 6cm/sec.  
B, Recording of strain rate, which represents the rate of deformation; the peak negative strain rate 
(arrow) was -1.3/sec. 
C, Strain recording, which is the integration of the strain rates; the negative peak strain (arrow) 
occurred slightly after aortic valve closure (AVC). The normal strain value is usually more than -15 
percent. AVO= aortic valve opening. 
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Tissue tracking, also known as displacement, is similar to strain, except it is the integral 
of the tissue velocity over a given time. It represents the distance a region of interest 
moves relative to its original location. 
                     In the normal heart, longitudinal strain rate values are similar from the base 
to the apex, unlike tissue velocity, which is higher at the base than at the apex. Every 
effort is made to ensure that the direction of tissue movement is less than 30 degrees from 
the direction of the beam, but this is technically challenging in the apical segments as the 
angle becomes wider. The narrow-sector angle approach on an individual wall obviates 
some of the above problems, which precludes concurrent comparison of contralateral 
segments. 
                     Strain imaging is similar to measuring the myocardial velocity gradient, 
which is limited to analyzing the myocardium that contracts in the direction that is 
parallel with the ultrasound beam. However, better spatial resolution and a higher frame 
rate (up to 200 frames/s) in strain rate imaging allow simultaneous calculation of the 
strain rate of the myocardium within a selected sector, which can be color coded. A 
curved cursor can be placed along the entire circumference of the LV to analyze regional 
strain rate. However, accurate measurements of strain rate depend on properly aligning 
the ultrasound beam so it is parallel with the direction of myocardial motion. 
 
SPECKLE TRACKING ECHOCARDIOGRAPHY 
                     Speckle tracking is a method for quantifying myocardial motion in various 
planes using 2D images. Reflection, scattering, and interference of the ultrasound beam 
in the myocardial tissue produce a speckle formation. Myocardial regions with unique 
speckle patterns in the gray scale 2D image can be tracked from frame to frame 
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throughout the cardiac cycle. This allows assessment of LV rotational motion, often 
referred to as torsion or twist. The spiral shape of the LV myocardial fibers results in a 
complex three-dimensional (3D) torsion mechanism for systolic contraction and 
untwisting for diastolic relaxation. The LV myocardium consists of two layers. The 
subendocardial layer wraps around the LV cavity in the direction of a right-handed helix, 
and the subepicardial layer wraps around in the direction of a left-handed helix. When 
viewed from the LV apex, apical rotation is counterclockwise and basal rotation is 
clockwise during systole. An analogy for LV contraction is the motion of wringing out a 
wet towel with your hands. As the two hands twist the ends of the towel in opposite 
directions Speckle tracking is an alternative method for quantification of LV systolic, and 
potentially diastolic, function. It also is another method for measuring strain using 2D 
images instead of the TDI method described above. Speckle tracking does not have the 
limitation of angle dependence that TDI-derived strain measurements have. 
 
TISSUE DOPPLER IMAGING (TDI) AND STRAIN IMAGING OF LEFT 
ATRIUM3 
                       The haemodynamic function of the left atrium (LA) 3 primarily modulates 
the left ventricular (LV) filling through its three components: a reservoir component 
during ventricular systole, a conduit component during early ventricular diastole, and a 
booster pump component during late ventricular diastole. The change of the LA function 
in different phases can be assessed non-invasively by echocardiography, using not only 
conventional methods such as changes in LA area and volume, but also novel techniques 
such as tissue Doppler imaging (TDI) and strain imaging. Tissue Doppler imaging 
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quantifies regional tissue motion velocity whereas strain and strain rate represent the 
extent of local tissue deformation and its rate, respectively. These novel technologies 
have been validated for the assessment of both global and regional 
LV function and have recently been applied to the evaluation of regional LA function. 
From an electromechanical perspective, echocardiographic parameters that assess LA 
mechanical function may provide a greater understanding of atrial performance and its 
relationship with ventricular function. 
 
Assessment of left atrial and appendage function by tissue Doppler imaging 3. 
                       Both spectral pulse TDI or two-dimensional colour-coded TDI can be 
applied to generate a myocardial velocity curve to assess a regional LA function, by 
placing a small sample volume at an atrial segment of interest, usually about 2 mm for 
measuring velocity and preferably not more than 12 mm of length for strain and strain 
rate, because of its thin-walled structure. Unlike the spectral pulse TDI that has a better 
temporal resolution but can measure only one segment at a time, colour-coded TDI 
images can be processed offline and offer simultaneous multi-segment analyses of 
velocities and other TDI-derived parameters, such as strain and strain rate. Thus, different 
LA walls with their corresponding levels from the mitral annulus can be compared and 
assessed, in particular by offline analysis of colour TDI, such as septal and lateral walls 
in an apical four-chamber view, anterior and inferior walls in a two-chamber view. The 
atrial myocardial velocity curve consists of three major deflections: ventricular systolic 
(Sa), early ventricular diastolic (Ea), and late ventricular diastolic (atrial contraction, Aa) 
waves. In addition, the three components in strain and strain-rate imaging can also be 
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readily identified. The Aa-wave has been regarded as a direct measure of regional active 
atrial contraction on the longitudinal axis, which might be less load dependent. The Sa 
and Ea waves may represent the passive expansion and emptying components of the LA 
function. The feasibility and reproducibility of TDI parameters, in particular the peak 
velocity (VAa) and peak strain rate (SRAa) of the active atrial contraction, have been 
demonstrated in previous studies, in which both the inter- and intra-observer variability 
for measuring the VAa were reported to be within 10%.Although the velocity data could 
be easily obtained in nearly all patients, strain rate measurements were only feasible in 
about 95% of patients due to the relatively higher noise-to-signal ratio 
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FIGURE 2 Assessment of regional atrial myocardial function by tissue Doppler imaging. 
The sample volume was placed at the mid-level of inter-atrial septum on colour tissue 
Doppler imaging image to reconstitute the myocardial velocity (A), strain (B), and strain 
rate (C) curves. They consist of ventricular systolic (Sa-wave), ventricular early diastolic 
(Ea-wave), and late diastolic (atrial contraction, Aa-wave) components 
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Left atrial appendage (LAA) 3 is a highly contractile structure with a pattern of 
contractions totally different from that of the LA main body. It is more compliant and 
therefore plays an important role in the LA reservoir function, especially during 
increases in the LA pressure or volume. Transoesophageal echocardiography (TEE) 
provides essential information about LAA structure and function. In addition to the LAA 
size, emptying and filling velocities, a characteristic triphasic TDI profile can be obtained 
readily at the tip, the septal, or lateral wall of the LAA by TEE. During sinus rhythm, 
there is an initial upward velocity in early atrial systole, i.e. in late ventricular diastole 
before the P-wave on ECG. This is followed by another upward velocity (after the P-
wave), the late systolic wave (LSW), that has a higher amplitude and corresponds to the 
late emptying flow of the LAA. Lastly, the negative late diastolic wave (LDW) occurs 
during the LAA filling. 
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FIGURE 3 Myocardial performance of left atrial appendage. The sample volume was 
placed at the septal wall of left atrial appendage where the pulsed tissue Doppler imaging 
was recorded in transoesophageal echocardiography. The profile is normally triphasic, 
which includes the initial upward velocity before the P-wave on electrocardiogram, 
followed by another upward velocity with higher amplitude after the P-wave 
(late systolic wave, LSW) and the negative velocity (late diastolic wave, LDW). 
 
 
                       Atrial fibrillation (AF) 1 is the most common sustained cardiac arrhythmia 
and may result in life-threatening complications such as stroke and heart failure. 
Unfortunately, treatment often comes too late—for example, when stroke is the first 
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manifestation of AF. Therefore, prediction and prevention of AF and its complications is 
essential. There has been an increase in the number of admissions to hospital for AF in 
recent years, demonstrating the need for primary prevention of new-onset AF. To enable 
primary  prevention strategies, we have to identify which patients are at increased risk for 
the development of AF. Observational population studies resulted in the discovery of 
clinical and echocardiographic parameters that are associated with the development of 
AF. However, the currently available risk stratification parameters have limited 
predictive value in the individual patient. Age or underlying heart disease may result in 
atrial dilatation or a depressed intra-atrial conduction. This will lead to an increased total 
atrial conduction time (TACT) 1 and facilitate AF. Recently, we validated a new non-
invasive echocardiographic method to determine the TACT, using transthoracic tissue 
Doppler imaging of the atria (the PA-TDI interval). We demonstrated that PA-TDI is an 
easy, fast and reliable method to estimate the TACT. 
 
                      This study demonstrates that the TACT 1as determined by tissue Doppler 
imaging may help to identify patients with a substrate vulnerable for AF. After correcting 
for possible confounders, the PA-TDI interval remains the most important predictor of 
new-onset AF. The longer the PA-TDI interval1, the higher the incidence of new-onset 
AF. In fact, each 10 ms increase of PA-TDI is associated with an increased risk of 
developing AF of 37–52% in the next 2 years. Therefore, the PATDI interval may 
become a useful measure for risk stratification to improve efficiency of primary 
prevention of AF. 
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FIGURE 4 
In the apical four-chamber view1, the pulsed-wave tissue Doppler sample was placed on 
the lateral wall of the left atrium just above the mitral annulus. The PA-TDI interval, 
defined as the time-interval from initiation of the electrocardiographic P wave 
recorded by the echo machine (lead II) to the peak of the A’ wave of the atrial tissue 
Doppler tracing (fig 4), was measured in three cardiac cycles and averaged. 
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ATRIAL FIBRILLATION 
 
ELECTROCARDIOGRAPHIC RECOGNITION. 
                       Atrial fibrillation is an arrhythmia characterized by seemingly disorganized 
atrial depolarizations without effective atrial contraction. It was once thought that all 
atrial fibrillation was caused by a single mechanism of multiple wavelets propagating in 
random fashion throughout the atria. It is now apparent that there are likely several 
mechanisms and that there may be some organization to atrial fibrillation. For example, 
in many patients, atrial fibrillation is caused by a focal discharge at rapid rates and 
fibrillatory conduction (heterogeneous conduction caused by rapidity of activation) 
through the atria. Nonetheless, all these potential mechanisms of atrial fibrillation have a 
common appearance on the ECG. During atrial fibrillation, electrical activity of the 
atrium can be detected on the ECG as small, irregular baseline undulations of variable 
amplitude and morphology, called f waves, at a rate of 350 to 600 beats/min. At times, 
small, fine, rapid f waves can occur and are detectable only by right atrial leads or by 
intracavitary or esophageal electrodes. The ventricular response is grossly irregular 
(irregularly irregular) and, in an untreated patient with normal AV conduction, is usually 
between 100 and 160 beats/min.  
                      In patients with WPW syndrome, the ventricular rate during atrial  
fibrillation can at times exceed 300 beats/min and lead to ventricular fibrillation. Atrial 
fibrillation should be suspected when the ECG shows supraventricular complexes at an 
irregular rhythm and no obvious P waves. The recognizable f waves probably do not 
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represent total atrial activity but depict only the larger vectors generated by the multiple 
wavelets of depolarization that occur at any given moment.  
                      Each recorded f wave is not conducted through the AV junction, so a rapid 
ventricular response comparable to the atrial rate does not occur. Many atrial impulses 
are concealed (not recorded in the ECG) because of a collision of wave fronts, or they are 
blocked in the AV junction without reaching the ventricles (i.e., concealed conduction, 
which accounts for the irregular ventricular rhythm). The refractory period and 
conductivity of the AV node are determinants of the ventricular rate. When the 
ventricular rate is very rapid or very slow, it may appear to be more regular. Even though 
conversion of atrial fibrillation to atrial flutter is accompanied by slowing of the atrial 
rate, an increase in the ventricular response can result, because more atrial impulses are 
transmitted to the ventricle as a result of less concealed conduction. Also, it is easier to 
slow the ventricular rate during atrial fibrillation than during atrial flutter with drugs such 
as digitalis, calcium antagonists, and beta blockers, because the increased concealed 
conduction makes it easier to produce an AV block. 
CLASSIFICATION11 
                       AF traditionally has been described as either paroxysmal or chronic. 
However, the definition of chronic varies greatly in the literature, often suggesting 
permanent AF. The American Heart Association (AHA), American College of 
Cardiology (ACC), and the European Society of Cardiology (ESC) have proposed a 
standardized classification scheme to describe AF, which we support. At the initial 
detection of AF, it may be difficult to be certain of the subsequent pattern of duration and 
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frequency of recurrences. Thus, a designation of first detected episode of AF is made on 
the initial diagnosis. When the patient has experienced two or more episodes, atrial AF is 
classified as recurrent. After the termination of an episode of AF, the rhythm can be 
classified as paroxysmal or persistent. Paroxysmal AF is characterized by self-
terminating episodes that generally last <7 days (most <24 hours), whereas persistent AF 
generally lasts >7 days and often requires electrical or pharmacologic cardioversion. AF 
is classified as permanent when it has failed cardioversion or when further attempts to 
terminate the arrhythmia are deemed futile. It might be more appropriate to use the term 
established rather than permanent, because these patients can undergo successful ablation 
to restore and maintain sinus rhythm precluding the concept of permanent. Although this 
classification scheme is generally useful, the pattern of AF may change in response to 
treatment. Thus, AF that has been persistent may become paroxysmal during 
pharmacologic therapy with antiarrhythmic medications. 
CLINICAL FEATURES 7. 
                      Atrial fibrillation is a common arrhythmia that is found in 1 percent of 
persons older than 60 years to more than 5 percent of patients older than 69 years. From 
the Framingham data, the lifetime risk of developing atrial fibrillation after age 40 has 
been found to be 26.0 percent (95 percent confidence interval [CI], 24.0 to 27.0 percent) 
for men and 23.0 percent (21.0 to 24.0 percent). Estimates are that 2.2 million Americans 
have atrial fibrillation, which occurs more commonly in men than in women. A history of 
congestive heart failure, valvular heart disease and stroke, left atrial enlargement, 
abnormal mitral or aortic valve function, treated systemic hypertension, and advanced 
age are independently associated with the prevalence of atrial fibrillation. Most recently, 
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obesity has been found as an additional risk factor for developing atrial fibrillation. Four 
important aspects of atrial fibrillation are treatable contributing factors, control of the 
ventricular rate, prevention of recurrences, and prevention of thromboembolic episodes. 
Occult or manifest thyrotoxicosis should be considered in patients with recent-onset atrial 
fibrillation. Atrial fibrillation can be intermittent or chronic and may be influenced by 
autonomic activity. Atrial fibrillation, whether it is persistent or intermittent, predisposes 
to stroke. Symptoms as a result of atrial fibrillation are determined by multiple factors, 
including the underlying cardiac status, the rapidity and irregularity of ventricular rate, 
and loss of atrial contraction. Physical findings include a slight variation in intensity of 
the first heart sound, absence of ‘a’ waves in the jugular venous pulse, and an irregularly 
irregular ventricular rhythm. Often, with fast ventricular rates, a significant pulse deficit 
appears (i.e., the auscultated apical rate is faster than the rate palpated at the wrist, pulse 
deficit, because each contraction is not sufficiently strong to open the aortic valve or 
transmit an arterial pressure wave through the peripheral artery). If the ventricular rhythm 
becomes regular in patients with atrial fibrillation, conversion to sinus rhythm, atrial 
tachycardia, or atrial flutter with a constant ratio of conducted beats or the development 
of junctional tachycardia or VT should be suspected. 
EMBOLIZATION AND ANTICOAGULATION 7. 
                       In addition to hemodynamic alterations, the risk of systemic emboli, 
probably arising in the left atrial cavity or appendage as a result of circulatory stasis, is an 
important consideration. Nonvalvular atrial fibrillation is the most common cardiac 
disease associated with cerebral embolism. In fact, almost half of cardiogenic emboli in 
the United States occur in patients with nonvalvular atrial fibrillation. The risk of stroke 
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in patients with nonvalvular atrial fibrillation is five to seven times greater than that in 
controls without atrial fibrillation. Overall, 20 to 25 percent of ischemic strokes are 
caused by cardiogenic emboli. Many studies have evaluated the risk of stroke in patients 
with atrial fibrillation and the benefits of anticoagulation and antiplatelet therapy. Patients 
with mitral stenosis and atrial fibrillation have a 4 to 6 percent incidence of embolism per 
year. Risk factors that predict stroke in patients with nonvalvular atrial fibrillation include 
a history of previous stroke or transient ischemic attack (relative risk, 2.5), diabetes 
(relative risk, 1.7), history of hypertension (relative risk, 1.6), and increasing age (relative 
risk, 1.4 for each decade). Patients with any of these risk factors have an annual stroke 
risk of at least 4 percent if untreated. Patients whose only stroke risk factor is congestive 
heart failure or coronary artery disease have stroke rates approximately three times higher 
than patients without any risk factors. Left ventricular (LV) dysfunction and a 
left atrial size larger than 2.5cm/m2 on echocardiographic examination are associated 
with thromboembolism. Patients younger than 60 to 65 years of age who have a normal 
echocardiogram and no risk factors have an extremely low risk for stroke (1 percent per 
year). Therefore, the risk of stroke in patients with lone atrial fibrillation—that is, 
idiopathic atrial fibrillation in the absence of any structural heart disease or any of the 
risk factors discussed previously—is relatively low. A scoring system to predict risk of 
stroke accounting for all these clinical risks has been proposed from an analysis of the 
Framingham Heart Study. 
                       The annual rate of stroke for the unanticoagulated control group in five 
large anticoagulation trials was 4.5 percent but was reduced to 1.4 percent (68 percent 
risk reduction) for the warfarin treated group (60 percent risk reduction in men; 84 
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percent risk reduction in women). Aspirin, 325 mg/day, produced a risk reduction of 44 
percent. The annual rate of major hemorrhage was 1 percent for the control group, 1 
percent for the aspirin group, and 1.3 percent for the warfarin group. No difference in 
stroke risk occurs between paroxysmal (intermittent) atrial fibrillation and sustained 
(chronic) atrial fibrillation. Anti-coagulation therapy is ap-proximately 50 percent more 
effective than aspirin therapy for the prevention of ischemic stroke in patients with atrial 
fibrillation. 
                      Risk factors for anticoagulant-associated intracranial hemorrhage include 
excessive anticoagulation and poorly controlled hypertension. Elderly individuals are at 
increased risk for anticoagulant-associated brain hemorrhage, especially if over 
anticoagulated. From these and other data, it appears that individuals younger than 60 
years of age without any clinical risk factors or structural heart disease (lone atrial 
fibrillation) do not require antithrombotic therapy for stroke prevention because of their 
low risk. The stroke rate is also low (less than 2 percent/year) in patients between the 
ages of 60 and 75 years with lone atrial fibrillation. These patients may be adequately 
protected from stroke by aspirin therapy. In very elderly (older than 75 years) patients 
with atrial fibrillation, anticoagulation should be used with caution and carefully 
monitored because of the potentially increased risk of intracranial hemorrhage. 
Nevertheless, elderly patients with atrial fibrillation are still likely to benefit from 
anticoagulation because they are at particularly high stroke risk. Food and drugs such as 
antibiotics and antiarrhythmics (e.g., amiodarone) can influence the effects of warfarin. 
Recommendations for antithrombotic therapy can be made. Any patient with atrial 
fibrillation who has risk factors for stroke (prior stroke or transient ischemic attack, 
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significant valvular heart disease, hypertension, diabetes, age older than 65 years, left 
atrial enlargement, coronary artery disease, or congestive heart failure) should be treated 
with warfarin anticoagulation to achieve an international normalized ratio (INR) of 2.0 to 
3.0 for stroke prevention if the individual is a good candidate for oral anticoagulation. 
Patients with contraindications to anticoagulation and unreliable individuals should be 
considered for aspirin treatment. Patients with atrial fibrillation who do not have any of 
the preceding risk factors have a low stroke risk (2 percent/year or less) and can be 
protected from stroke with aspirin. In patients older than 75 years, anticoagulation should 
be used with caution and monitored carefully to keep the INR less than 3.0 because of the 
risk of intracranial hemorrhage. 
                         The risk of embolism following cardioversion to sinus rhythm in patients 
with atrial fibrillation varies from 0 to 7 percent, depending on the underlying risk 
factors. This risk is independent of the mode of cardioversion, either by chemical (drug) 
or direct current (DC) shock. Patients at high risk are those with prior embolism, a 
mechanical valve prosthesis, or mitral stenosis. Low-risk patients are those younger than 
60 years without underlying heart disease. The high-risk group should receive chronic 
anticoagulation (see later), regardless of whether they will undergo cardioversion. 
Patients not in the low-risk group who have atrial fibrillation longer than 2 days should 
receive warfarin to achieve an INR of 2.0 to 3.0 for 3 weeks before elective cardioversion 
and for 3 to 4 weeks after reversion to sinus rhythm. An alternative strategy is to obtain a 
transesophageal echocardiogram to exclude the presence of an atrial thrombus. It appears 
that this technique predicts a group at low risk for the development of thromboembolism 
following cardioversion, provided that the patients are immediately treated with heparin 
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followed by therapeutic doses of warfarin. Anticoagulation with heparin has been 
recommended for emergency cardioversion when 3 weeks of anticoagulation or a 
transesophageal echocardiogram cannot be obtained. No matter which strategy is used, 
anticoagulation should be continued for at least 4 weeks following cardioversion, because 
atrial contractile function may not fully return until then. These suggestions must be 
individualized for a given patient. For example, patients at risk of trauma by virtue of 
occupation, participation in sports, and episodes of dizziness or syncope are at increased 
risk of bleeding if given anticoagulants and should probably not receive warfarin. 
Patients should be warned about taking any new drugs, such as nonsteroidal anti-
inflammatory agents, or dietary changes with foods containing vitamin K such as leafy 
vegetables, if they are receiving warfarin. There are no data to suggest that conversion to 
sinus rhythm eliminates the risk of thromboembolism and thus this should not be the sole 
purpose for doing so. In fact, data from the Atrial Fibrillation Follow-Up Investigation of 
Rhythm Management (AFFIRM) trial have suggested that the strategy of maintaining 
sinus rhythm is insufficient alone to prevent thromboembolism, and patients who are 
treated with a strategy of maintaining sinus rhythm should be continued on 
anticoagulation unless there is a contraindication.[12 ] Many patients can have 
asymptomatic recurrences of atrial fibrillation. Newer strategies for stroke prevention are 
being developed. Oral thrombin inhibitors (e.g., ximelagatran, melagatran) have been 
shown to be effective in preventing postoperative deep vein thrombosis and have been 
evaluated in a randomized trial for stroke prevention in atrial fibrillation. Although not 
yet approved for use, the potential advantage of these agents is their wider therapeutic 
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window not requiring monitoring, like warfarin. Left atrial occlusion, surgically or with a 
catheter-based system, is also being evaluated as a method for stroke prevention. 
MANAGEMENT 7. 
                      The goals of management of the patient with atrial fibrillation are to reduce 
the risk of thromboembolism (described earlier) and to control symptoms. The latter is 
accomplished by controlling the ventricular rate during atrial fibrillation and/or restoring 
and maintaining sinus rhythm. Currently, no clear benefit has been ascribed to one 
treatment strategy over the other (rate control versus rhythm control), particularly 
because antiarrhythmic drugs are only 50 to 70 percent effective and carry risks of 
proarrhythmia .Data from large clinical studies (e.g., AFFIRM, Pharmacologic 
Intervention in Atrial Fibrillation [PIAF], and Rate Control versus Electrical 
Cardioversion [RACE]) all have demonstrated that both treatment strategies are 
reasonable. In the largest of these studies, AFFIRM, 4060 patients with atrial fibrillation 
and risk factors for thromboembolism were randomized to either rhythm control or rate 
control treatment strategy, using standard pharmacological approaches. The study found 
no differences in mortality or quality of life between the two groups. In both groups, 
thromboembolic events occurred in those patients in whom anticoagulation was stopped. 
These studies compared treatment strategies and did not compare sinus rhythm to atrial 
fibrillation with rate control. In the AFFIRM trial, only 60 percent of the patients in the 
rhythm control arm were in sinus rhythm at follow-up, and patients were not rigorously 
monitored for atrial fibrillation recurrences between visits. The overall treatment strategy 
(i.e., ventricular rate control or restoration and maintenance of sinus rhythm) should be 
individualized for each patient and based on whether patients are 
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symptomatic from uncontrolled ventricular rates or from atrial fibrillation itself (i.e., loss 
of AV synchrony and atrial contraction) and risk for side effects from drugs. It can 
sometimes be difficult to determine whether a patient's symptoms are caused by rapid 
ventricular rates or the loss of atrial contraction. As a general rule, asymptomatic patients 
found to have atrial fibrillation on a routine ECG are not likely to require rhythm control, 
and rate control is usually sufficient. Ambulatory monitoring correlating the patient's 
ventricular response and rhythm to symptoms and exercise testing can be useful to this 
end. Trials of aggressive rate control or, conversely, cardioversion and maintenance of 
sinus rhythm are sometimes necessary to make this determination. Intolerance to 
medications or excessive risk in one strategy may necessitate switching strategies. As 
stated earlier, a rhythm control strategy should not be an alternative to anticoagulation 
therapy to reduce stroke risk. Many elderly patients tolerate atrial fibrillation well 
without therapy, because the ventricular rate is slow as a result of concomitant AV nodal 
disease. These patients often have associated sick sinus syndrome, and the development 
of atrial fibrillation represents a cure of sorts. Such patients may demonstrate serious 
supraventricular and ventricular arrhythmias or asystole after cardioversion, so the 
likelihood of establishing and maintaining sinus rhythm should be weighed against the 
risks of cardioversion or other forms of therapy. 
ACUTE MANAGEMENT 7. 
                      A patient with atrial fibrillation discovered for the first time should be 
evaluated for a precipitating cause, such as thyrotoxicosis, mitral stenosis, pulmonary 
emboli, or pericarditis. The patient's clinical status determines initial therapy, the 
objectives being to slow the ventricular rate and/or restore atrial systole. If sudden onset 
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of atrial fibrillation with a rapid ventricular rate results in acute cardiovascular 
decompensation, electrical cardioversion is the initial treatment of choice. For other 
patients, the decision to cardiovert is largely based on the individual clinical situation. 
The need to restore sinus rhythm must be weighed against the likelihood of successful 
cardioversion and long-term maintenance of sinus rhythm. Maintenance of sinus rhythm 
after cardioversion is influenced by the duration of atrial fibrillation and, in some adults, 
atrial dilation. Animal studies have indicated that atrial fibrillation begets atrial 
fibrillation—the longer the patient has atrial fibrillation, the greater the likelihood that it 
will remain because of a process called electrophysiological remodeling. Similar 
electrophysiological abnormalities can be demonstrated in patients following short 
episodes of atrial fibrillation, but the mechanism(s) and clinical significance remain 
unknown. Although parameters such as atrial size and duration of atrial fibrillation 
predict the success of cardioversion in population studies, enlarged atria and atrial 
fibrillation of long duration are not absolute contraindications to attempted cardioversion. 
Internal cardioversion via intracavitary catheters can be effective when transthoracic 
shocks fail, particularly in obese patients or in those with significant pulmonary disease. 
However, with the advent of biphasic external defibrillators, the success rates and the 
energy requirement for cardioversion have improved and the need to perform internal 
cardioversions has decreased. Alternatively, antiarrhythmic drugs that lower defibrillation 
thresholds such as ibutilide can be used to pretreat the patient and increase the success of 
DC cardioversion. Because atrial contraction may not return immediately after restoration 
of electrical systole, clinical improvement may be delayed. DC cardioversion establishes 
normal sinus rhythm in more than 90 percent of patients, but sinus rhythm remains for 12 
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months in only 30 to 50 percent. Patients with atrial fibrillation of less than 12 months' 
duration have a greater chance of maintaining sinus rhythm after cardioversion. For 
patients who do not require emergent cardioversion, chemical cardioversion with IV 
antiarrhythmic drugs is effective in 35 to 75 percent of patients, depending on the 
population studied.  Although procainamide has been used extensively for years, no well-
controlled studies have been performed to determine its efficacy. Outside the United 
States, IV flecainide has been used with good results. IV amiodarone appears to be less 
effective, with no difference in conversion rates from placebo. IV ibutilide is also 
effective in about 35 to 75 percent of patients, depending on the population studied. In 
the absence of decompensation, the patient can be treated with drugs such as digitalis, 
beta blockers, or calcium antagonists to maintain a resting apical rate of 60 to 80 
beats/min that does not exceed 100 beats/min after slight exercise. The combined use of 
digitalis and a beta blocker or calcium antagonist can be helpful in slowing the 
ventricular rate. 
                       Digitalis may be more effective if associated LV dysfunction is present; 
without such dysfunction, a beta blocker may be preferable to control the ventricular rate. 
LONG-TERM MANAGEMENT  7 
                      For the rate control strategy, digitalis, calcium channel blockers (diltiazem 
and verapamil) and beta blockers can be used alone or in combination. For chronic 
management, digitalis is usually insufficient for adequate rate control during periods of 
exertion. One should not rely on a resting heart rate during an office visit as the sole 
evaluation of the adequacy of rate control. Ambulatory monitoring and/or exercise testing 
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can be useful to confirm adequate rate control during activity. In some patients with 
frequent recurrence and rapid ventricular rates not controlled by drugs or in 
patients intolerant to drugs, modification or elimination of AV nodal conduction by 
radiofrequency catheter ablation and implantation of a rate-adaptive VVI pacemaker 
(VVIR) is acceptable rate control therapy. Whenever possible, atrial or dual-chamber 
pacing is preferable, because the incidence of atrial fibrillation and stroke appears to be 
reduced compared with VVI pacing. If a decision to maintain sinus rhythm has been 
made, class IA, IC, and III (amiodarone, sotalol) agents can be used to terminate acute-
onset atrial fibrillation and prevent recurrences of atrial fibrillation. No one drug appears 
clearly superior, and selection is often based on the side effect profile and risk of 
proarrhythmia. This appears to be true for newer drugs such as azimilide and dofetilide as 
well, although comparative trials have not yet been done. Most antiarrhythmic drugs 
increase the likelihood of maintaining sinus rhythm from about 30 to 50 percent to 50 to 
70 percent of patients per year after cardioversion. Some rather recent data suggest that 
sotalol is less effective than amiodarone or 1C agents. Class IA agents are often poorly 
tolerated and are rarely used in the long-term management of atrial fibrillation. As a 
general rule, for patients without structural heart disease, IC agents (propafenone and 
flecainide) are well-tolerated and reasonable first-line agents for maintenance of sinus 
rhythm. For patients with structural heart disease, amiodarone, dofetilide, or sotalol may 
be reasonable first-line therapies to maintain sinus rhythm. Occasionally, these agents 
(especially class IC agents) can “convert” the atrial fibrillation to atrial flutter, which can 
be slower than usual because of the drug. In these patients, a strategy of an atrial flutter 
ablation (see later) and continuation of the antiarrhythmic drug can be effective for 
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maintaining sinus rhythm, with up to an 80 percent efficacy. Before electrical 
cardioversion, an antiarrhythmic agent is often administered for a few days to help 
prevent relapse of atrial fibrillation, as well as to convert some patients to sinus 
rhythm. In patients with occasional episodes of persistent atrial fibrillation (requiring 
cardioversion), a “pill in the pocket” approach can be effective.  In these patients, either 
flecainide or propafenone, usually at high doses, is administered only after the onset of 
atrial fibrillation to convert the atrial fibrillation. For those patients who fail drug therapy, 
catheter ablation approaches have been applied successfully. Radiofrequency ablation 
aimed at electrical isolation of the pulmonary veins or wide area ablation of the posterior 
left atrium around the pulmonary veins is 70 to 85 percent effective in patients with 
paroxysmal atrial fibrillation and 50 to 70 percent effective in patients with persistent 
atrial fibrillation in short-term follow-up studies. The surgical maze procedure has been 
used to eliminate atrial fibrillation, particularly in combination with valve surgery, with a 
high success rate. Newer surgical techniques using specially designed tools (e.g., 
radiofrequency [RF] clamp, cryoablation, RF pen, high-intensity ultrasound) to replace 
the traditional cut-and-sew maze procedure enable the procedure to be done faster and 
through more limited incisions. 
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                                      PATIENTS AND METHODS  
INCLUSION CRITERIA 
159 Patients who came to our cardiology out patient department between April 2008 and 
March 2010 were randomly selected and included in the study. 
EXCLUSION CRITERIA 
Patients with history of AF, atrial flutter, atrial tachycardia, age <18 years, previous 
pacemaker implantation or an implantable cardioverter-defibrillator were excluded from 
the study. 
The following parameters were studied 
 Age 
 Sex  
 Occupation 
 Socioeconomic status 
  Diabetes 
  Hypertension 
 Coronary artery disease 
  Rheumatic heart disease 
  Underlying disease like chronic obstructive pulmonary disease (COPD), 
thromboembolic events, heart failure, myopathies etc were studied. 
  Medication use ( beta blockers, verapamil, diuretics, anti arrhythmic etc) 
 ECG  
1. Heart rate(bpm) 
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2. P-wave duration 
3. PR interval 
4. QRS duration (ms)) 
 
 Tissue Doppler imaging 
1. PA-TDI interval - (The time from the initiation of the P wave on the ECG 
(lead II) to the peak of A' wave on the lateral left atrial tissue Doppler 
tracing obtained in apical 4-chamber view) was measured  
2. Maximal A’ –wave velocity (cm/s)( lateral left atrial tissue Doppler 
tracing) 
 Dimensions ( Echo cardiography)  
1. Aorta diameter(mm) 
2. Left atrial dimension(mm)  
3. Left ventricular end diastolic diameter(mm) 
4. Left ventricular end systolic diameter(mm) 
5. Inter ventricular septum width (mm) 
6. Posterior wall width(mm) 
7. Left ventricular mass(gm)  
8. End diastolic volume(ml) 
9. End systolic volume(ml) 
10. Caval vein(mm) 
 Left ventricular function  
1. Left ventricular ejection fraction (%) 
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2. Hypokinesia   
 
 Mitral valve Doppler assessments        
1. Maximal E – wave velocity (m/s)  
2. E – wave deceleration time (ms)  
3. Maximal A – wave velocity (m/s)  
4. E/A ratio  
 Valvular disorders were studied. 
 
TOTAL ATRIAL CONDUCTION TIME (TACT): 
TACT  is the time elapsed between the initiation of atrial depolarisation and the last 
depolarisation of the same activation front and it incorporates both conduction slowing 
and atrial dilatation 
TACT is measured non-invasively by transthoracic tissue Doppler imaging of the 
Atria by measuring the PA-TDI interval. 
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FIGURE 5 Shows the measurement of PA-TDI interval by tissue Doppler imaging 
 
 
 
 
 
 
 The measurements were made using Philips IE 33 ECHO Machine. 
 Patients were followed up in the review OPD once in 2 months and rhythm                                         
      Recorded by taking ECG. 
 If any doubt holter recordings were done. 
 Patients were advised to report to us whenever there is palpitation or other signs  
      Of arrhythmia. 
PA-TDI interval (the time from the initiation of the P wave on the 
ECG (lead II) to the peak of A' wave on the lateral left atrial tissue 
Doppler tracing obtained in apical 4-chamber view 
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STATISTICAL ANALYSIS 
 
 Continuous variables are reported as mean (SD) and categorical variables as 
observed number of patients (%). 
 Cox regression univariate analysis used to compare patients who developed 
and not developed AF. 
 Fisher’ s  exact test used to measure p value.  
 
                                  
 
                                          RESULTS 
 
 The average age of the patients was 52.2 yrs, 
 Male to female ratio was 1.5:1, 
 Most of them belonged to low socioeconomic status, 
 20 patients (12 %) developed new-onset AF.  
 These patients had a longer PA-TDI interval than patients who remained in sinus 
rhythm (176 ms vs. 148 ms, p < 0.05). 
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 TABLE -2   PATIENT CHARACTERISTICS WERE SHOWN BELOW 
SI 
NO 
CHARACTERISTICS ALL 
PATIENTS 
(N=159) 
NO AF 
DURING 
FOLLOW-
UP 
(N=139) 
AF 
DURING 
FOLLOW-
UP 
(N=20) 
P 
VALUE 
1 HYPERTENSION 95(60%) 87(63%) 8(40%) 0.0857 
2 CAD 16(10%) 15(11%) 1(5%) 0.6954 
3 DIABETES 20(13%) 18(13%) 2(10%) 1.0 
4 THROMBOEMBOLIC 
EVENTS 
8(5%) 7(5%) 1(5%) 1.0 
5 RHD 70(44%) 60(43%) 10(50%) 0.6335 
6 HEART FAILURE 14(8%) 10(7%) 4(20%) 0.0795 
7 COPD 60(38%) 56(37%) 4(20%) 0.0899 
8 MYOPATHIES 10(6%) 8(6%) 2(10%) 0.6156 
 
1. The above table shows patient characteristics with predominantly hypertension, 
rheumatic heart disease, and chronic obstructive pulmonary disese(COPD). 
2. Among the patients with myopathies (total no of patients-10), restrictive 
cardiomyopathy were-2, hypertropic obstructive cardiomyopathy-2, dilated 
cardiomyopathy were 6. 
3. Some of the patients who were hypertensive also had diabetes and (COPD). 
Among them some had heart failure and thromboembolic events which is 
explained in the table above. 
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4. Age, diabetes, hypertension, Coronary artery disease (CAD), thromboembolic       
events, Rheumatic heart disease( RHD ), Heart failure, Chronic obstructive 
pulmonary disease (COPD), myopathies and  medication use were comparable 
between the groups which developed & not developed atrial fibrillation. 
 
5. Maximal A’ –wave velocity (cm/s) (lateral left atrial tissue Doppler tracing) 
were Rheumatic heart disease (total no of patients-70),mean maximal A’-wave    
      velocity is 8.4 cm/s, restrictive cardiomyopathy(total no of patients -2)-7.1 cm/s,    
      systemic hypertension(total no of patients -95) – 8.9 cm/s, hypertropic  
      obstructive cardiomyopathy(total no of patients -2)-7.5 cm/s, dilated  
      cardiomyopathy (total no of patients-6)-7.4 cm/s, patients who had systemic  
      thromboembolism(total no of patients-8)-9.3 cm/s, chronic obstructive  
      pulmonary disease(total no of patients-60) – 9.5 cm/s. 
6. Left atrial diameter(mean) measured by 2d echo were, rheumatic heart disease-
4.46cm, restrictive cardiomyopathy-5.9 cm, hypertropic obstructive 
cardiomyopathy- 3.25cm, systemic hypertension-3.8cm, patients who had 
systemic thromboembolism-4.6 cm, dilated cardiomyopathy-5.25 cm. 
7. Left ventricular ejection fraction (mean %) measured (m-mode) were rheumatic 
heart disease-55.1%, restrictive cardiomyopathy-61.5%, hypertropic obstructive 
cardiomyopathy-65%, dilated cardiomyopathy-31.8%,  systemic hypertension-
57.9%, patients who had heart failure-48%. 
8. Patients who were hypertensive had mean left ventricular posterior wall 
thickness – 10.4cms, and mean interventricular septal thickness-10.71cms, 
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hypertropic obstructive cardiomyopathy mean left ventricular posterior wall 
thickness-11.5cm, mean interventricular septal thickness- 26.5cms. 
9. Mitral valve Doppler measurements, Maximal E – wave velocity (m/s) and 
Maximal A – wave velocity (m/s) (mean values) were rheumatic heart disease-
0.55&0.38 m/s, restrictive cardiomyopathy -1.5&0.5 m/s, hypertropic 
obstructive cardiomyopathy- 0.35& 0.95 m/s, dilated cardiomyopathy- 
1.4&0.73 m/s, systemic hypertension-0.68&0.74 m/s, and patients who had 
coronary heart disease – 0.63&0.72m/s respectively. 
10. E/A ratio(mean) were rheumatic heart disease -1.3, restrictive cardiomyopathy-
3, hypertropic obstructive cardiomyopathy -0.7, dilated cardiomyopathy-2.03, 
systemic hypertension-0.91, and patients who had coronary heart disease – 1.01. 
 
11. New onset AF was more common in patients with rheumatic heart disease 
(50%) (Especially with mitral regurgitation), chronic obstructive pulmonary 
disease (20%), restrictive cardiomyopathy (10%) and patients with previous 
history of Heart failure (20%). These findings are explained by the table below. 
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TABLE 3 
 
PATIENTS WHO DEVELOPED ATRIAL FIBRILLATION (N=20) 
SI NO DISEASE NO (%) 
1 RHD   10 ( 50%) 
2 COPD 4 (20%) 
3 RESTRICTIVE CARDIOMYOPATHY 2 (10%) 
4 PRIOR CHF 4 (20%) 
 
 Potential confounders were adjusted and it was found that prolonged PA-TDI was 
independently associated with new-onset Atrial Fibrillation (AF).  
 With a PA-TDI interval <136 ms (n = 22), (p < 0.05) none had AF. 
 With a PA-TDI interval >190 ms (n = 18), 12 (66%) had AF. 
 With a PA-TDI interval 136-160 ms (n = 77), 4 (5.2%) had AF. 
 With a PA-TDI interval 161-189 ms (n = 42), 4 (9.5%) had AF. 
 
 
 
 
 
 
 
 
 
 58
 
The following diagram explains these findings. 
FIGURE 6 
INCIDENCE OF NEW-ONSET ATRIAL FIBRILLATION (AF) IN PATIENTS 
CLASSIFIED ACCORDING TO THE PA-TDI INTERVAL MEASURED AT 
BASELINE 
0
10
20
30
40
50
60
70
<136(22) 136-160(77) 161-189(42) >190(18)
% - Y AXIS
         PA-TDI Interval in ms (NO of patients)  
 
Cox regression showed that PA-TDI was independently associated with new-onset AF 
(OR=1.370; 95% CI 1.032 to 1.723; p=0.028).  
 
Thus the PA – TDI interval independently predict the new onset atrial fibrillation. 
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DISCUSSION 
 
The hemodynamic function of the left atrium (LA) 3 primarily modulates the left 
ventricular (LV) filling through its three components: a reservoir component during 
ventricular systole, a conduit component during early ventricular diastole, and a booster 
pump component during late ventricular diastole. Left atrial appendage (LAA) is a highly 
contractile structure with a pattern of contractions totally different from that of the LA 
main body. It is more compliant and therefore plays an important role in the LA reservoir 
function, especially during increases in the LA pressure or volume  
Atrial fibrillation (AF) is the most common cardiac arrhythmia associated with an 
at least two-fold increase in morbidity and mortality, and occurs in 0.4% of the general 
population, increasing to 5% in those >65 years old. With the loss of atrial booster pump 
function, the LA–LV pressure gradient during early LV filling is enhanced by elevation 
of the LA pressure to maintain stroke volume. Thus, a reduction in both LA compliance 
and volume has been observed with the onset of AF that further decreases cardiac 
function and increases the risk of thrombo-embolism. 
Importance of predicting atrial fibrillation: 
Atrial fibrillation 3 constitutes the commonest cardiac rhythm disorder and is the 
major determinant of outcome in valvular, myocardial, and ischemic heart disorders. 
AF can result in life-threatening complications such as stroke and heart failure. 
Therefore, the application of adequate individual treatment is essential. Unfortunately, 
many patients have silent AF. As a result, treatment may come too late. Adequate 
administration of oral anticoagulation will reduce the risk of thrombo-embolic 
complications by 60%. Therefore, one could imagine that prophylactic anticoagulation 
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could be applied in patients with a high risk of developing AF. However, this hypothesis 
needs to be confirmed in prospective randomized trials. 
Observational population1 studies such as the Framingham Heart study, the 
Manitoba Follow-up study and the Cardiovascular Health study reported several clinical 
and echocardiographic parameters that are associated with the development of new onset 
AF. The clinical factors associated with new-onset AF are higher age, male sex, the 
presence of diabetes, hypertension, congestive heart failure, valve disease and coronary 
artery disease.  
In our study, new onset AF was more common in patients with rheumatic heart 
disease (50%) (especially with mitral regurgitation), chronic obstructive pulmonary 
disease (20%), restrictive cardiomyopathy (10%), and patients with previous history of 
heart failure (20%). 
Atrial electrical activation2, as assessed by the PA-start interval, began at the RA 
and followed through the IAS, to the inferior and posterior LA walls. This is the known 
normal electrical activation process, as obtained by invasive electrophysiology 
techniques. 
The atrial fibrillation cycle length (AFCL) is a critical parameter for the 
perpetuation and termination of AF. Currently, the total atrial activation time1, as 
indicated by the P-wave duration using signal-averaged (SA) electrocardiogram (ECG) 
(SA-ECG), is the most powerful predictor of atrial fibrillation. However, because of 
practical limitations, this technique is not used in clinical routine. 
Left atrial enlargement, increased left ventricular wall thickness1, left ventricular 
diastolic dysfunction and a reduced left ventricular fractional shortening are predictive 
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echocardiographic parameters for new-onset AF. There is no simple tool available to 
predict the onset this arrhythmia. Electrophysiological parameters are too complex and 
can not be obtained in bedside. 
The identification of an abnormal electrical activation process could be of interest 
in some patients with atrial fibrillation or other supra-ventricular tachy-arrhythmias, in 
whom the premature atrial contraction acting as a triggering factor could be aggravated 
by local delayed conduction. Several studies have shown the independent prognostic 
value of atrial function measurements in subsets of patients. 
Karl et al12, even as early as in 1978 in an article published by the AHA in 
Circulation showed that prolonged atrial conduction was a major predisposing factor for 
the development of Atrial flutter. 
The multiple wavelet re-entry theory1 postulated the existence of multiple 
spatially discrete activation fronts (wavelets) resulting in re-entry at changing locations as 
the basis for AF. A decreased conduction velocity, leads to a shorter wavelength of the 
reentrant wave fronts. An increased atrial size can harbour more wave fronts of a certain 
size at the same time. Both will favour AF.  
The change of the LA function in different phases can be assessed non-invasively 
by echocardiography, using conventional methods such as changes in LA area and 
volume, but they lack specificity.  
Novel techniques such as tissue Doppler imaging (TDI) TVE-derived variables of 
atrial mechanical function may have an additional role for facilitating the assessment of 
atrial function and consequently in the process of risk stratification. Tissue Doppler 
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imaging can be used to measure total atrial conduction time. A prolonged PA-TDI 
interval may predict the development of new-onset AF. 
De Vos et al1  showed that an increased Total Atrial Conduction Time, which is 
the time elapsed between the initiation of atrial depolarization and the last depolarization 
of the same activation front, incorporates both conduction slowing and atrial dilatation, 
and may therefore reflect the existence of a substrate vulnerable for AF. Determination of 
the TACT may therefore be better than the classical predictors of AF since it might not 
only demonstrate the presence of underlying disease but also its severity. Thus, different 
LA walls with their corresponding levels from the mitral annulus can be compared and 
assessed, in particular by offline analysis of colour TDI, such as septal and lateral walls 
in an apical four-chamber view, anterior and inferior walls in a two-chamber view. The 
atrial myocardial velocity curve consists of three major deflections: ventricular systolic 
(Sa), early ventricular diastolic (Ea), and late ventricular diastolic (atrial contraction, Aa) 
waves. (The Aa-wave has been regarded as a direct measure of regional active atrial 
contraction on the longitudinal axis, which might be less load dependent. The Sa and Ea 
waves may represent the passive expansion and emptying components of the LA 
function. Approaching regional left atrial function by tissue Doppler velocity and strain 
imaging were described very early by Qing Zhang et al3. 
In our study, TDI was done by placing a 2mm sample volume PWD at the lateral 
wall of the left atrium, just below the mitral annulus. 
P-wave duration on the 12-lead ECG and A’ wave using the mitral Doppler flow 
signal provide estimates of the TACT.  PA-TDI1 determined by transthoracic tissue 
Doppler imaging had the best correlation with the ‘‘gold standard’’ (SA-ECG P-wave 
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duration). Previous studies presented a similar parameter measuring the interval between 
the onset of the P wave on the ECG till the onset of the A’ wave of the left atrial lateral 
wall instead of the peak of the A’ wave (atrial electromechanical interval or AEMI). But, 
studies done later proved that the peak of the A’ wave is a better pointer than the onset of 
the wave. In our study, the peak of the A’ was used and the distance in milliseconds from 
the onset of the ‘p’ wave of the ECG was used. 
The main new findings of this study2 are as follows: 
(1) Some TVE-derived variables indirectly reflect the atrial electrical activation 
that follows the known activation process as revealed by invasive electrophysiology.  
(2) The regional and global atrial mechanical function is explained by an upward 
movement of the atrial walls at the region near the A-V ring with a continuous reduction 
of this movement towards the upper levels of atrial walls.  
(3) The atrial mechanical function is quite similar in all LA walls; however, all 
indices of mechanical function were higher in the RA than in the LA.  The difference in 
the atrial velocities at different sites was attributed to an atrial free-wall motion higher 
than that of the bounded IAS. Furthermore, the larger pectinate muscle in the RA can 
perhaps generate a more pronounced and sustained longitudinal movement in the 
relatively low pressure system of the right ventricle.  
(4) The present study showed that all atrial walls actively moved upwards from 
the region of the A-V ring at late diastole, with a reduction of this movement towards the 
upper parts, thus empting the atria and contributing towards the last part of filling of the 
LV. This longitudinal movement of the atrial walls is probably related to the longitudinal 
endocardial muscular fibers along the walls of the LA and RA. The more pronounced 
 64
longitudinal movement in the RA may be explained in part by the larger pectinate 
muscles in the RA, but also by the lower pressures in the heart's right side. To what 
extent circumferential contraction of the atrial muscle fibers might contribute to atrial 
mechanical function is unknown. Anatomically, the large amount of circumferential 
muscle fibers present in the vestibules of the RA and LA might imply some kind of 
circumferential or radial contraction of the atria.  
(5) No correlations were found between 2-D- and TVE derived variables of atrial 
mechanical function, as was also found in a previous study by Donald et al. Although 2-
D-derived variables measure volumes and volume-derived indices that might indicate 
some kind of atrial mechanical force, it was surprising to find no correlations between the 
variables obtained by the two different techniques. This might indicate that the velocities 
and the displacements registered from all atrial walls by TVE are less dependent on 
volume loading conditions than 2D derived variables and therefore could be used as 
reliable measurement of pure atrial mechanical contraction or inotropism. However, most 
of the TVE-derived variables expressing atrial mechanical function had good values of 
repeatability and measurement error. Assessing atrial mechanical function by measuring 
volumes is time consuming and depends on age, gender, and body surface area. In 
addition, atrial volume indices are also dependent on loading conditions and are not 
necessarily more reproducible than TVE-derived variables.  
Our study demonstrates that the TACT as determined by tissue Doppler imaging 
may help to identify patients with a substrate vulnerable for AF. After correcting for 
possible confounders, the PA-TDI interval remains the most important predictor of new-
onset AF. The longer the PA-TDI interval, the higher the incidence of new-onset AF. 
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Therefore, the PATDI interval may become a useful measure for risk stratification to 
improve efficiency of primary prevention of AF. 
In a study by De Vos et al1, they demonstrate that a short PA-TDI interval of 
<130 ms seems to prevent patients from developing AF. Therefore, one could 
hypothesize that these patients are not candidates for primary prevention. Patients with a 
PA-TDI interval of >165ms have a reasonable chance of developing AF and could be 
candidates for primary prevention using ‘‘upstream’’ cardiovascular drugs. A PA-TDI 
interval 190 ms makes patients very vulnerable for the development of AF. These 
patients could be treated with prophylactic anticoagulation. 
In our study, 20 patients (12 %) developed new-onset AF. These patients had a 
longer PA-TDI interval than patients who remained in sinus rhythm (176ms vs. 148 ms, p 
< 0.05). With a PA-TDI interval <136 ms, none had AF (p < 0.05). 
Other uses of measurement of total atrial conduction time: 
The assessment of pure mechanical atrial function by means of atrial wall 
movements may give more concrete clues about the recovery process of atrial 
electromechanical function after conversion for atrial fibrillation and flutter and can give 
additional patho-physiological insights on the thrombo-embolic process that occur in 
some of those patients. TVE-derived parameters may also give additional patho-
physiological information on the process of atrial electromechanical remodeling that 
occurs in patients with sustained supra-ventricular tachy-arrhythmias 
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Ischemic heart disease3: 
Atrial contractile dysfunction appears early in ischemic heart disease (IHD), irrespective 
of previous myocardial infarction, co-existing systolic dysfunction, or severity of 
diastolic dysfunction. Yu et al, found that the VA’ measured at mid-level of the IAS and 
the lateral LA in the apical four chamber view were drastically reduced in 118 patients 
with IHD when compared with 100 normal subjects. A poor LV-ejection fraction and the 
presence of a restrictive LV filling pattern were the most important determinants of LA 
contractile dysfunction in IHD.  
In our study, 10% of our patients had Coronary artery disease, and a significant 
number developed AF during follow-up. 
Advanced heart failure and cardiac resynchronization therapy3: 
Gabriel et al showed that the LA mechanical function can be modified by heart 
failure treatment, such as cardiac resynchronization therapy (CRT), which is of proven 
benefit to advanced heart failure patients with prolonged QRS duration. 
In this study, 8% of the study patients were included as they had heart failure. 
20% of those patients developed AF during follow-up. Even these patients might improve 
with CRT therapy.  
Mitral stenosis and mitral regurgitation3: 
Due to inflow obstruction, the atrial booster pump contributes less to LV filling in 
mitral stenosis even during sinus rhythm, despite a proportional increase, with increasing 
severity, in the LA preload. The impaired atrial reservoir and pump function are 
associated with a reduction in LA compliance and intrinsic myocardial contractility. In 
addition, the LAA is inevitably affected in mitral stenosis with reduced contribution to 
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overall LA emptying fraction and increased risk of thrombus formation. In a study by 
Wang et al, published in 2005, the LSW and LDW tissue velocities recorded during sinus 
rhythm at the lateral wall or at the tip of the LAA were markedly reduced in subjects with 
mitral stenosis when compared with normal subjects. Systolic velocity was further 
decreased in patients with spontaneous echo contrast (SEC) in the LAA than those 
without. In this present study, the bulk of the patients were suffering from RHD (44%) 
and the incidence of atrial fibrillation during follow-up was also high in those patients, in 
concordance with the previous studies (50% developed new onset AF). 
 
LIMITATIONS 
 Study was not compared with electro physiological measurements. 
For the future: 
Further refinement of the TVE technique are necessary not only to identify the 
mechanical activation atrial sequence during normal sinus rhythm, but also to identify the 
origin and the activation sequence of supra-ventricular ectopic beats and in patients with 
RA, IAS or bi-atrial pacing. Our study was first of its kind in our region and needs to be 
compared with electrophysiological measurements. Thus, TVE could be an excellent 
adjunct to invasive electrophysiological techniques in selecting adequate patients and in 
the evaluation of atrial electromechanical consequences of RA, IAS or bi-atrial pacing. 
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CONCLUSIONS  
 
 Tissue Doppler imaging can be used to measure total atrial conduction time. 
 A prolonged PA-TDI interval may predict the development of new-onset AF. 
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                         GLOSSARY AND ACRONYMS 
AF- Atrial fibrillation 
COPD-chronic obstuctive pulmonary disease 
CAD- Coronary artery disease 
HOCM-Hypertrophic obstructive cardiomyopathy   
RHD-Rheumatic Heart disease 
TDI- Tissue doppler imaging 
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                                                 PROFORMA  
Age                       Sex                    Occupation                           date 
RISK FACTORS 
 Diabetes                     Hypertension                 Coronary artery disease 
 Rheumatic heart disease           chronic obstructive pulmonary disease (COPD), 
thromboembolic events,      heart failure,                    myopathies. 
 Medication use  
ECG  
Heart rate(bpm) 
P-wave duration 
PR interval 
QRS duration (ms) 
Tissue Doppler imaging 
PA-TDI interval   
Maximal A’ –wave velocity (cm/s) 
Dimensions ( Echo cardiography)  
Aorta diameter(mm) 
Left atrial dimension(mm)  
Left ventricular end diastolic diameter(mm) 
Left ventricular end systolic diameter(mm) 
Inter ventricular septum width (mm) 
Posterior wall width(mm) 
Left ventricular mass(gm)  
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End diastolic volume(ml) 
End systolic volume(ml) 
Caval vein(mm) 
Left ventricular function  
Left ventricular ejection fraction (%) 
Hypokinesia   
 
Mitral valve Doppler assessments        
Maximal E – wave velocity (m/s)  
E – wave deceleration time (ms)  
Maximal A – wave velocity (m/s)  
E/A ratio  
Valvular disorders - DETAILS 
 
 
